← Back to Clinical Trials
Recruiting NCT05250557

NCT05250557 Prognostic Impact of Lesion-specific Hemodynamic Index in Patients With Coronary Artery Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05250557
Status Recruiting
Phase
Sponsor Seoul National University Hospital
Condition Coronary Artery Disease
Study Type OBSERVATIONAL
Enrollment 2,429 participants
Start Date 2021-08-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Fractional flow reserve

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,429 participants in total. It began in 2021-08-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators aim to investigate the additive prognostic value of lesion-specific hemodynamic index such as ΔFFR, non-hyperemic pressure ratio such as RFR, over % diameter stenosis and FFR according to treatment strategy, and to find the prognostic implications of post-PCI FFR after adjustment of various clinical and disease characteristics, and to construct a comprehensive risk prediction model for post-PCI outcomes.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥20 years 2. All comers who underwent successful FFR measurement and pullback tracing Exclusion Criteria: 1. Chronic renal failure (estimated glomerular filtration rate \<30) 2. ST-elevation myocardial infarction within 72 hours or previous coronary artery bypass graft surgery history 3. Primary myocardial or valvular disease 4. Left ventricular ejection fraction \< 30% 5. Hemodynamically unstable clinical conditions 6. Life expectancy \< 2 years

Contact & Investigator

Central Contact

Bon-Kwon Koo, MD, PhD

✉ bkkoo@snu.ac.kr

📞 +82-2-2072-2062

Principal Investigator

Bon-Kwon Koo, MD, PhD

PRINCIPAL INVESTIGATOR

Seoul National University Hospital

Frequently Asked Questions

Who can join the NCT05250557 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05250557 currently recruiting?

Yes, NCT05250557 is actively recruiting participants. Contact the research team at bkkoo@snu.ac.kr for enrollment information.

Where is the NCT05250557 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT05250557 clinical trial?

NCT05250557 is sponsored by Seoul National University Hospital. The principal investigator is Bon-Kwon Koo, MD, PhD at Seoul National University Hospital. The trial plans to enroll 2,429 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology